3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial - Inria - Institut national de recherche en sciences et technologies du numérique
Conference Papers Year : 2022

3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial

Florence Monville
  • Function : Author
Sylvie van Hulst
  • Function : Author
  • PersonId : 1095238
Frédéric Vely
  • Function : Author
  • PersonId : 929854
S. Bokobza
  • Function : Author
Lamia Ghezali
  • Function : Author
  • PersonId : 959309
J. Fieschi-Meric
  • Function : Author
Fichier principal
Vignette du fichier
2022_PIONEER_ESMO_IO_MiniOral_edited_metadata.pdf (1.28 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03928784 , version 1 (12-01-2023)

Identifiers

  • HAL Id : hal-03928784 , version 1

Cite

Fabrice Barlesi, Laurent Greillier, Florence Monville, C Audigier-Valette, S. Martinez, et al.. 3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial. 2022 ESMO Immuno-Oncology Congress, Dec 2022, Geneva, Switzerland. ⟨hal-03928784⟩
154 View
34 Download

Share

More